Synapse - Miguel-Angel Perales

Results (943)

ALLO-647 for lymphodepletion in the allogeneic CAR T setting: Safety experience with ALLO-501/501A in patients (pts) with relapsed/refractory (r/r) large B-cell and follicular lymphomas

Meeting Abstract

Locke, F. L.; Munoz, J. L.; Tees, M. T.; Lekakis, L. J.; Eradat, H. A.; de Vos, S.; Nath, R.; Stevens, D. A.; Malik, S. A.; Shouse, G. P.; more...
Blood (2023)

Fulltext@MSK | Save

Trem-cel, a CRISPR/Cas9 gene-edited allograft lacking CD33, shows rapid primary engraftment with CD33-negative hematopoiesis in patients with high-risk acute myeloid leukemia (AML) and avoids hematopoietic toxicity during gemtuzumab ozogamicin (GO) maintenance post-hematopoietic cell transplant (HCT)

Meeting Abstract

DiPersio, J.; Cooper, B. W.; Suh, H. C.; Koura, D.; Bernard, L.; Shah, N. N.; Walter, R. B.; Perales, M. A.; Mapara, M.; Tamari, R.; more...
Blood (2023)

Fulltext@MSK | Save

Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell LyLisocabtagene maraleucel in relapsed/refractory large B-cell lymphoma: Real world analysis from the Cell Therapy Consortiummphoma: Real World Analysis from the Cell Therapy Consortium

Meeting Abstract

Riedell, P. A.; Grady, C.; Nastoupil, L. J.; Luna, A.; Ahmed, N.; Maziarz, R. T.; Hu, M.; Brower, J.; Hwang, W. T.; Schuster, S. J.; more...
Blood (2023)

Fulltext@MSK | Save

Real-world outcomes of brexucabtagene autoleucel ( brexu-cel) for relapsed or refractory (R/R) adult B-cell acute lymphoblastic leukemia (B-cell ALL): Evidence from the CIBMTR registry

Meeting Abstract

Bezerra, E.; Itani, T.; Wudhikarn, K.; Perales, M. A.; Yang, Y.; Gergis, U.; Aribi, A.; Hill, L. C.; Jain, N.; Leonard, J. T.; more...
Blood (2023)

Fulltext@MSK | Save

Rabbit antithymocyte (rATG) exposure and outcomes after hematopoietic cell transplantation: A real world experience from BMT CTN 1202

Meeting Abstract

Lakkaraja, M.; Mauguen, A.; Hosszu, K. K.; McAvoy, D.; Stewart, V.; Schmidt, G.; Levine, J.; Perales, M. A.; Giralt, S. A.; Baker, K. S.; more...
Blood (2023)

Fulltext@MSK | Save

Topical ruxolitinib for chronic cutaneous GvHD: Promising results of a phase 2 clinical trial

Meeting Abstract

Markova, A.; Papadopoulos, E. B.; Dusza, S.; Ostojić, J.; Ai, R.; Maier, T.; Lacouture, M.; Tamari, R.; Gyurkocza, B.; Shaffer, B. C.; more...
Blood (2023)

Fulltext@MSK | Save

TNC/Kg and CD34+/Kg cell dose impact on patient engraftment after allogeneic transplant with conventional bone marrow; Better predictability of graft content needed

Meeting Abstract

Davis, E.; Feuer, E.; Rapoport, C.; Lobaugh, S.; Devlin, S. M.; Archer, A.; Chinapen, S.; Federman, J.; Kelly, A.; Klein, E.; more...
Blood (2023)

Fulltext@MSK | Save

High progression-free survival with low relapse rates after double-unit cord blood transplantation in patients with high-risk AML

Meeting Abstract

Politikos, I.; Fingrut, W. B.; Brown, S.; Chinapen, S.; Quach, S.; Dahi, P. B.; Gyurkocza, B.; Jakubowski, A. A.; Papadopoulos, E. B.; Ponce, D. M.; more...
Blood (2023)

Fulltext@MSK | Save

An inflammatory biomarker signature reproducibly predicts CAR-T treatment failure in patients with aggressive lymphoma across the ZUMA trials cohorts

Meeting Abstract

Raj, S.; Xie, J.; Fei, T.; Song, Q.; Kim, J. J.; To, C.; van den Brink, M. R. M.; Perales, M. A.; Mattie, M.; Shouval, R.
Blood (2023)

Fulltext@MSK | Save

A phase II trial of prophylactic anakinra to prevent neurotoxicity in patients receiving anti-CD19 CAR T-cell therapy for relapsed or refractory lymphoma: Final results from cohort 2

Meeting Abstract

Nath, K.; Devlin, S. M.; Sauter, C. S.; Palomba, M. L.; Shah, G. L.; Dahi, P. B.; Lin, R. J.; Scordo, M.; Perales, M. A.; Leslie, L. A.; more...
Blood (2023)

Fulltext@MSK | Save